Sonoma Biotherapeutics rallies $265m Series B
Sonoma Biotherapeutics, a developer of regulatory T cell therapies, has secured $265 million in Series B financing.
Sonoma Biotherapeutics, a developer of regulatory T cell therapies, has secured $265 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination